ClinicalTrials.gg
CompletedNCT06855576Updated Jul 1, 2026Results posted

Bioequivalence Study of Paracetamol With Oral Single Dose Administration in Healthy Adult Subjects Under Fasting Conditions

A Phase 1 interventional study of Paracetamol ODT and Alvedon film-coated tablet in Fever and Pain, sponsored by HALEON. Completed at 1 site in Germany. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-01.

Sponsored by HALEON · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
54
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 31 studies testing acetaminophen in Fever — 1 open to participants now, 1 under way, none of them phase 3. Acetaminophen · Fever.

Enrollment
22nd of 31
54 · median 100
Started
2025
the only one that year
Phase 1
3 of 31
none open now
Registered
30th of 31
by date
Lead sponsor
1 of 31
HALEON

Among the 31 studies testing acetaminophen in Fever, this one is the 22nd largest by enrollment, is the only one that started in 2025, is one of 3 in phase 1, and was the 30th registered.

Fever

438 studies on the registry are indexed under Fever; 55 are open to participants now.

Browse Fever studies →

Open to participants now

1 of the 31 studies testing acetaminophen in Fever is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About acetaminophen

Acetaminophen: first FDA approval 1968 (NEOPAP). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 38 Fever studies recruiting now, 18 (47%) set no upper age limit and 14 (37%) stop at 75 or younger; 22 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies testing acetaminophen in Fever, or all of them as a file.
02

Study summary

This study aims to evaluate the bioequivalence of new formulated orodispersible tablet (ODT) containing 500 milligram (mg) paracetamol in comparison to the European marketed Alvedon (paracetamol) 500 mg film-coated tablets and the Australian marketed Panadol (paracetamol) 500 mg film-coated tablets as reference products.

Read the detailed description

This will be a single center, open-label, randomized (order of treatments), balanced, 3-period, 3-sequence, single dose, change-over trial with oral administration under fasting conditions separated by a washout period of at least 72 hours. Fifty-four healthy participants of both sexes (27 male, 27 female) are intended to be randomized to obtain 42 evaluable participants. The investigational products will be administered in fasted state as single oral doses of 500 mg paracetamol tablet. 1 tablet of test and 1 film-coated tablet of reference 1 and 1 film-coated tablet of reference 2 will be administered in a cross-over manner. Blood sampling will be performed over 24-hour post dose in order to characterize pharmacokinetic parameters.

03

Conditions studied

  • Fever
  • Pain

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written , after having been informed about benefits and potential risks of the clinical trial, as well as details of the insurance taken out to cover the participants participating in the clinical trial.
  • Sex: male/female.
  • Age: 18 to 55 years (including)
  • Body-mass index (): more than or equal to (>=)18.5 kilogram per meter square (kg/m\^2) and less than or equal to (\<=) 30.0 kg/m\^2.
  • Body weight: >= 50.0 kg for males and >= 45.0 kg for females.
  • Good state of health.
  • Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
  • Female participant of and at risk for pregnancy must agree to use a highly effective method of throughout the study and for at least 7 days after the last dose of assigned treatment.
  • Non-smoker or ex-smoker for at least 3 months (including non-nicotine vapers, nicotine chewing gum or pouches or nicotine replacement therapy).

Exclusion criteria

Exclusion Criteria:

  • Safety Concerns

    1. Existing cardiac and/or haematological diseases or pathological findings, which might interfere with the safety or tolerability of the active ingredient.
    2. Existing renal diseases or pathological findings, which might interfere with the safety or tolerability, and/or pharmacokinetics of the active ingredient.
    3. Current evidence of ongoing hepatic disease or impaired hepatic function at screening. A participant will be excluded if more than one of the following lab value deviations are found: 1) (AST) (>= 1.2 [ULN]), Alanine transaminase (ALT) (>= 1.2 ULN), 2) Gamma-glutamyl transferase (GGT) (>= 1.2 ULN), Alkaline phosphatase (ALP) (>= 1.2 ULN), 3) total (greater than [>] 2.00 milligrams per deciliter (mg/dL), except in case of existing Morbus Gilbert-Meulengracht deduced from anamnesis/medical history) or creatine kinase (>= 3 ULN), and creatinine > 0.1 mg/dL ULN (limit of > 0.1 mg/dL correspondents to of > 9 micromole per liter [μmol/l] ULN). A single deviation from the above values is acceptable and will not exclude the candidate, unless specifically advised by the investigator.
    4. Existing gastrointestinal diseases or pathological findings, which might interfere with the safety, tolerability, absorption and/or pharmacokinetics of the active ingredient.
    5. History of relevant central nervous system (CNS) and/or psychiatric disorders and/or currently treated CNS and/or psychiatric disorders.
    6. History or clinical evidence at screening of pancreatic injury or pancreatitis.
    7. History of inflammatory bowel disease or gastrointestinal bleeding including peptic ulcers.
    8. Diagnosis of systemic lupus erythematosus, thyroid diseases, secondary Raynaud's syndrome; known hyperkalemia.
    9. Evidence of urinary obstruction (example, due to benign prostate hyperplasia) or difficulty in voiding at screening.
    10. Status of glutathione depletion (eating disorder, cystic fibrosis, [HIV] infection, starvation, cachexia) due to metabolic deficiencies.
    11. Oral surgery within 4 weeks of dosing, dental work or extractions within 2 weeks of dosing, or presence of any (as determined by the principal investigator or designee) oral pathology including lesions, sores or inflammation.
    12. History of major gastrointestinal tract surgery such as gastrectomy, gastroenterostomy, bowel resection, gastric bypass, gastric stapling or gastric banding (note: this is not applicable for minor abdominal surgery without significant tissue resection, example, appendectomy and herniorrhaphy).
    13. Participants, who report a frequent occurrence of migraine attacks.
    14. Acute or chronic diseases which may interfere with the pharmacokinetics of the medicinal product (IMP).
    15. Clinically relevant chronic or acute infectious illnesses or febrile infections within two weeks prior to start of the study.
    16. History or current evidence of renal disease or impaired renal function at screening as indicated by abnormal levels of serum creatinine (> 1.43 mg/dL) or blood urea nitrogen (BUN) (>= 35 mg/dL) or the presence of clinically significant abnormal urinary constituents (example, albuminuria).
    17. Systolic blood pressure less than (\<) 90 or > 139 millimeter of mercury (mmHg).
    18. Diastolic blood pressure \< 50 or > 89 mmHg.
    19. Heart rate \< 50 beats per minute (bpm) or > 90 bpm.
    20. interval (QTc) interval > 450 milliseconds (ms) for men and > 470 ms for women.
    21. value \< 12.0 grams per deciliter (g/dL) for males and \< 11.5 g/dL for females.
    22. Evidence or history of medication overuse headache, or allergic disease to medication within the last 5 years that may increase the risk associated with study participation.
    23. Laboratory values out of normal range unless the deviation from normal is judged as not relevant for the clinical trial by the investigator.
    24. Positive anti-HIV-test (if positive to be verified by western blot), surface antigen (HBs-AG) test and anti-hepatitis B core immunoglobulin M (HBc IgM) or anti- virus (HCV) test.
    25. Known allergic reactions to the active ingredients used or to constituents of the pharmaceutical preparations.
    26. Any history of asthma, urticaria, or other significant allergic diathesis or allergic reaction to any other pain reliever/fever reducer. Participant with uncomplicated seasonal allergic rhinitis can be accepted if expected allergy season is clearly outside enrollment/treatment period.
    27. History of severe allergies or multiple drug allergies unless it is judged as not relevant for the clinical trial by the investigator.
  • Lack of suitability for the clinical trial

    1. History of illegal or legal drug abuse within 1 year prior to screening or recreational use of soft drugs (such as marijuana, codeine) within 1 month or hard drugs (such as cocaine, phencyclidine [PCP], crack, any opioid derivatives such as heroin or fentanyl, and amphetamine derivatives) within 3 months prior to screening.
    2. Positive alcohol, cotinine or drug test at screening examination.
    3. History of alcohol abuse in the last 5 years or regular intake of alcoholic food or beverages of >= 24 gram (g) pure ethanol for men or >= 12 g pure ethanol for women per day.
    4. Participants who are on a diet which could affect the pharmacokinetics of the active ingredient.
    5. Regular intake of beverages or food containing xanthine derivatives or xanthine-related compounds (example, coffee, tea, caffeine-containing sodas and chocolate), equivalent to >= 500 milligram (mg) xanthine per day.
    6. Performance of strenuous physical exercise (body building, high performance sports) from 2 weeks prior to admission and throughout the entire study.
    7. Participant reports consumption of any drug metabolizing enzyme (example, Cytochrome P450 3A4 () or other cytochrome P450 enzymes) inducing or inhibiting aliments, beverages or food supplements (example, broccoli, Brussels sprouts, grapefruit, grapefruit juice, star fruit, St. John's Wort and so on) within 2 weeks prior to admission to the unit.
    8. Use of any systemic or topical medication (including over the counter [OTC] medications, herbal remedies, cannabidiol cosmetics and any anticholinergic medicines or other medicines that may cause dry mouth) within 2 weeks or within less than 10 times the elimination half-life of the respective drug (whichever is longer) before first scheduled study drug administration, or is anticipated to require any concomitant medication during that period or at any time throughout the study.
    9. Any history of long-term treatment with carbamazepine, phenobarbitone, phenytoin, primidone, rifampicin, St John's Wort or other drugs that induce liver enzymes.
    10. Any vaccination, including Coronavirus disease (COVID)-19 vaccine, within 14 days prior to the first dose.
    11. Donation of plasma within 7 days prior to dosing or donation or loss of 500 milliliter (mL) or more of whole blood within 8 weeks prior to dosing.
    12. Participation in a clinical trial in which they have tried an IMP, a medical device or a marketed medicinal product during the last 6 months prior to individual enrolment of the participant.
    13. Simultaneous participation in another clinical trial with active ingredients, medical devices or marketed medicinal products.
  • For female participants with only

    1. Positive pregnancy test at screening examination.
    2. Pregnant or lactating women.
    3. Female participants who do not agree to apply highly effective methods.
  • Administrative reasons

    1. Close affiliation with the sponsor or the investigational site; example, a close relative of the investigator, dependent person (example, employee of or student at the investigational site), employee of the sponsor or affiliates.
    2. Participants who are unable to understand the written and verbal instructions, in particular regarding the risks and inconveniences they will be exposed to during their participation in the clinical trial.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
54 participants (actual)

Study arms

  • Experimental
    Test Product

    Participants will be randomly assigned as per cross-over design to receive oral administration of one paracetamol ODT (test product) on day 1 of period 1, one Alvedon film-coated tablet (reference product 1) on day 1 of period 2 and one Panadol film-coated tablet (reference product 2) on day 1 of period 3, each under fasting conditions. There will be at least 72 hours of washout between each period (no more than 7 days).

    Drug: Paracetamol ODT · Drug: Alvedon film-coated tablet · Drug: Panadol film-coated Tablet

  • Active comparator
    Reference Product 1

    Participants will be randomly assigned as per cross-over design to receive oral administration of one Alvedon film-coated tablet (reference product 1) on day 1 of period 1, one Panadol film-coated tablet (reference product 2) on day 1 of period 2 and one paracetamol ODT (test product) on day 1 of period 3, each under fasting conditions. There will be at least 72 hours of washout between each period (no more than 7 days).

    Drug: Paracetamol ODT · Drug: Alvedon film-coated tablet · Drug: Panadol film-coated Tablet

  • Active comparator
    Reference Product 2

    Participants will be randomly assigned as per cross-over design to receive oral administration of one Panadol film-coated tablet (reference product 2) on day 1 of period 1, and one paracetamol ODT (test product) on day 1 of period 2 and one Alvedon film-coated tablet (reference product 1) on day 1 of period 3, each under fasting conditions. There will be at least 72 hours of washout between each period (no more than 7 days).

    Drug: Paracetamol ODT · Drug: Alvedon film-coated tablet · Drug: Panadol film-coated Tablet

Interventions

  • DrugParacetamol ODT

    Experimental Paracetamol 500 mg ODT

  • DrugAlvedon film-coated tablet

    Marketed Paracetamol 500 mg film-coated tablet

  • Marketed Paracetamol 500 mg film-coated tablet

06

What researchers measure

Primary outcomes

  1. Maximum Observed Concentration (Cmax) for Paracetamol ODT (Test) Versus (vs.) Paracetamol (Alvedon Film-coated Tablet) (Reference 1)

    Cmax was defined as maximum observed post-dose plasma concentration for paracetamol. Blood samples were collected at indicated timepoints for the analysis of Cmax. Pharmacokinetic (PK) parameters were determined by non-compartmental analysis.

    Time frame: Within one hour prior to dosing, at 5, 10, 15, 20, 25, 30, 35, 40, 50, 60, 75, 90, 120, 150, 180 minutes and at 4, 5, 6, 8, 10, 12, 14, 16 and 24 hours following dosing in each treatment period

  2. Area Under the Concentration vs. Time Curve From Dosing Time to the Last Measurement Time Point (AUC0-tlast) for Paracetamol ODT (Test) vs. Paracetamol (Alvedon Film-coated Tablet) (Reference 1)

    AUC0-tlast was defined as area under the concentration vs. time curve from dosing time to the last measurement time point with a concentration value above the lower limit of quantitation, calculated by means of the linear up/log down method (linear trapezoidal rule for increases in concentration/logarithmic trapezoidal rule for decreases in concentrations). Blood samples were collected at indicated timepoints for the analysis of AUC0-tlast. PK parameters were determined by non-compartmental analysis.

    Time frame: Within one hour prior to dosing, at 5, 10, 15, 20, 25, 30, 35, 40, 50, 60, 75, 90, 120, 150, 180 minutes and at 4, 5, 6, 8, 10, 12, 14, 16 and 24 hours following dosing in each treatment period

  3. Time to Reach Maximum Concentration (Tmax) for Paracetamol ODT (Test) vs. Paracetamol (Alvedon Film-coated Tablet) (Reference 1)

    Blood samples were collected at indicated timepoints for the analysis of tmax. PK parameters were determined by non-compartmental analysis.

    Time frame: Within one hour prior to dosing, at 5, 10, 15, 20, 25, 30, 35, 40, 50, 60, 75, 90, 120, 150, 180 minutes and at 4, 5, 6, 8, 10, 12, 14, 16 and 24 hours following dosing in each treatment period

  4. Cmax for Paracetamol ODT (Test) vs. Paracetamol (Panadol Film-coated Tablet) (Reference 2)

    Cmax was defined as maximum observed post-dose plasma concentration for paracetamol. Blood samples were collected at indicated timepoints for the analysis of Cmax. PK parameters were determined by non-compartmental analysis.

    Time frame: Within one hour prior to dosing, at 5, 10, 15, 20, 25, 30, 35, 40, 50, 60, 75, 90, 120, 150, 180 minutes and at 4, 5, 6, 8, 10, 12, 14, 16 and 24 hours following dosing in each treatment period

  5. AUC0-tlast for Paracetamol ODT (Test) vs. Paracetamol (Panadol Film-coated Tablet) (Reference 2)

    AUC0-tlast was defined as area under the concentration vs. time curve from dosing time to the last measurement time point with a concentration value above the lower limit of quantitation, calculated by means of the linear up/log down method (linear trapezoidal rule for increases in concentration/logarithmic trapezoidal rule for decreases in concentrations. Blood samples were collected at indicated timepoints for the analysis of AUC0-tlast). PK parameters were determined by non-compartmental analysis.

    Time frame: Within one hour prior to dosing, at 5, 10, 15, 20, 25, 30, 35, 40, 50, 60, 75, 90, 120, 150, 180 minutes and at 4, 5, 6, 8, 10, 12, 14, 16 and 24 hours following dosing in each treatment period

  6. Tmax for Paracetamol ODT (Test) vs. Paracetamol (Panadol Film-coated Tablet) (Reference 2)

    Blood samples were collected at indicated timepoints for the analysis of tmax. PK parameters were determined by non-compartmental analysis.

    Time frame: Within one hour prior to dosing, at 5, 10, 15, 20, 25, 30, 35, 40, 50, 60, 75, 90, 120, 150, 180 minutes and at 4, 5, 6, 8, 10, 12, 14, 16 and 24 hours following dosing in each treatment period

Secondary outcomes

  1. Area Under the Plasma Concentration vs. Time Curve Calculated From Time Zero to Infinity [AUC (0-inf)] for Paracetamol ODT (Test)

    AUC (0-inf) equal to(=) AUC0-tlast addition(+) AUCexpol, where AUCexpol = Clast/Lz, where Clast was observed concentration at the last time point with a concentration value above the lower limit of quantitation, directly taken from measured concentration values and Lz was apparent terminal elimination rate constant determined by log-linear regression(Lz); the regression generally involved at least 3 consecutive measurable concentrations that decreased over time. Blood samples were collected at indicated timepoints for the analysis of AUC (0-inf). PK parameters were determined by non-compartmental analysis.

    Time frame: Within one hour prior to dosing, at 5, 10, 15, 20, 25, 30, 35, 40, 50, 60, 75, 90, 120, 150, 180 minutes and at 4, 5, 6, 8, 10, 12, 14, 16 and 24 hours following dosing in each treatment period

  2. AUC (0-inf) for Paracetamol (Alvedon Film-coated Tablet) (Reference 1)

    AUC (0-inf)= AUC0-tlast + AUCexpol, where AUCexpol = Clast/Lz, where Clast was observed concentration at the last time point with a concentration value above the lower limit of quantitation, directly taken from measured concentration values and Lz was apparent terminal elimination rate constant determined by log-linear regression; the regression generally involved at least 3 consecutive measurable concentrations that decreased over time. Blood samples were collected at indicated timepoints for the analysis of AUC (0-inf). PK parameters were determined by non-compartmental analysis.

    Time frame: Within one hour prior to dosing, at 5, 10, 15, 20, 25, 30, 35, 40, 50, 60, 75, 90, 120, 150, 180 minutes and at 4, 5, 6, 8, 10, 12, 14, 16 and 24 hours following dosing in each treatment period

  3. AUC (0-inf) for Paracetamol (Panadol Film-coated Tablet) (Reference 2)

    AUC (0-inf)= AUC0-tlast + AUCexpol, where AUCexpol = Clast/Lz, where Clast was observed concentration at the last time point with a concentration value above the lower limit of quantitation, directly taken from measured concentration values and Lz was apparent terminal elimination rate constant determined by log-linear regression; the regression generally involved at least 3 consecutive measurable concentrations that decreased over time. Blood samples were collected at indicated timepoints for the analysis of AUC (0-inf). PK parameters were determined by non-compartmental analysis.

    Time frame: Within one hour prior to dosing, at 5, 10, 15, 20, 25, 30, 35, 40, 50, 60, 75, 90, 120, 150, 180 minutes and at 4, 5, 6, 8, 10, 12, 14, 16 and 24 hours following dosing in each treatment period

  4. AUCexpol% for Paracetamol ODT (Test)

    AUCexpol%= AUCexpol multiplied by (\*)100/AUC0-inf, where AUCexpol = Clast/Lz. Blood samples were collected at indicated timepoints for the analysis of AUCexpol%. PK parameters were determined by non-compartmental analysis.

    Time frame: Within one hour prior to dosing, at 5, 10, 15, 20, 25, 30, 35, 40, 50, 60, 75, 90, 120, 150, 180 minutes and at 4, 5, 6, 8, 10, 12, 14, 16 and 24 hours following dosing in each treatment period

  5. AUCexpol% for Paracetamol (Alvedon Film-coated Tablet) (Reference 1)

    AUCexpol%= AUCexpol\*100/AUC0-inf, where AUCexpol = Clast/Lz. Blood samples were collected at indicated timepoints for the analysis of AUCexpol%. PK parameters were determined by non-compartmental analysis.

    Time frame: Within one hour prior to dosing, at 5, 10, 15, 20, 25, 30, 35, 40, 50, 60, 75, 90, 120, 150, 180 minutes and at 4, 5, 6, 8, 10, 12, 14, 16 and 24 hours following dosing in each treatment period

  6. AUCexpol% for Paracetamol (Panadol Film-coated Tablet) (Reference 2)

    AUCexpol%= AUCexpol\*100/AUC0-inf, where AUCexpol = Clast/Lz. Blood samples were collected at indicated timepoints for the analysis of AUCexpol%. PK parameters were determined by non-compartmental analysis.

    Time frame: Within one hour prior to dosing, at 5, 10, 15, 20, 25, 30, 35, 40, 50, 60, 75, 90, 120, 150, 180 minutes and at 4, 5, 6, 8, 10, 12, 14, 16 and 24 hours following dosing in each treatment period

  7. Lz for Paracetamol ODT (Test)

    Lz was an apparent terminal elimination rate constant determined by log-linear regression; the regression generally involved at least 3 consecutive measurable concentrations that decreased over time. Blood samples were collected at indicated timepoints for the analysis of Lz. PK parameters were determined by non-compartmental analysis.

    Time frame: Within one hour prior to dosing, at 5, 10, 15, 20, 25, 30, 35, 40, 50, 60, 75, 90, 120, 150, 180 minutes and at 4, 5, 6, 8, 10, 12, 14, 16 and 24 hours following dosing in each treatment period

  8. Lz for Paracetamol (Alvedon Film-coated Tablet) (Reference 1)

    Lz was an apparent terminal elimination rate constant determined by log-linear regression; the regression generally involved at least 3 consecutive measurable concentrations that decreased over time. Blood samples were collected at indicated timepoints for the analysis of Lz. PK parameters were determined by non-compartmental analysis.

    Time frame: Within one hour prior to dosing, at 5, 10, 15, 20, 25, 30, 35, 40, 50, 60, 75, 90, 120, 150, 180 minutes and at 4, 5, 6, 8, 10, 12, 14, 16 and 24 hours following dosing in each treatment period

  9. Lz for Paracetamol (Panadol Film-coated Tablet) (Reference 2)

    Lz was an apparent terminal elimination rate constant determined by log-linear regression; the regression generally involved at least 3 consecutive measurable concentrations that decreased over time. Blood samples were collected at indicated timepoints for the analysis of Lz. PK parameters were determined by non-compartmental analysis.

    Time frame: Within one hour prior to dosing, at 5, 10, 15, 20, 25, 30, 35, 40, 50, 60, 75, 90, 120, 150, 180 minutes and at 4, 5, 6, 8, 10, 12, 14, 16 and 24 hours following dosing in each treatment period

  10. Apparent Terminal Elimination Half-life (t1/2) for Paracetamol ODT (Test)

    t1/2 = ln(2) / Lz. Blood samples were collected at indicated timepoints for the analysis of t1/2. PK parameters were determined by non-compartmental analysis.

    Time frame: Within one hour prior to dosing, at 5, 10, 15, 20, 25, 30, 35, 40, 50, 60, 75, 90, 120, 150, 180 minutes and at 4, 5, 6, 8, 10, 12, 14, 16 and 24 hours following dosing in each treatment period

  11. t1/2 for Paracetamol (Alvedon Film-coated Tablet) (Reference 1)

    t1/2 = ln(2) / Lz. Blood samples were collected at indicated timepoints for the analysis of t1/2. PK parameters were determined by non-compartmental analysis.

    Time frame: Within one hour prior to dosing, at 5, 10, 15, 20, 25, 30, 35, 40, 50, 60, 75, 90, 120, 150, 180 minutes and at 4, 5, 6, 8, 10, 12, 14, 16 and 24 hours following dosing in each treatment period

  12. t1/2 for Paracetamol (Panadol Film-coated Tablet) (Reference 2)

    t1/2 = ln(2) / Lz. Blood samples were collected at indicated timepoints for the analysis of t1/2. PK parameters were determined by non-compartmental analysis.

    Time frame: Within one hour prior to dosing, at 5, 10, 15, 20, 25, 30, 35, 40, 50, 60, 75, 90, 120, 150, 180 minutes and at 4, 5, 6, 8, 10, 12, 14, 16 and 24 hours following dosing in each treatment period

07

Results

Posted Jul 1, 2026

Participant flow

This study was conducted at a single center in Germany.

Treatment Period 1 (1 Day)
Participant flow — Treatment Period 1 (1 Day)
MilestoneTest Product/ Reference Product 2/ Reference Product 1Reference Product 1/ Test Product/ Reference Product 2Reference Product 2/ Reference Product 1/ Test Product
Started181818
Completed181818
Not completed000
Washout Period 1 (3 Days)
Participant flow — Washout Period 1 (3 Days)
MilestoneTest Product/ Reference Product 2/ Reference Product 1Reference Product 1/ Test Product/ Reference Product 2Reference Product 2/ Reference Product 1/ Test Product
Started181818
Completed181718
Not completed010
Withdrew: Withdrawal by subject010
Treatment Period 2 (1 Day)
Participant flow — Treatment Period 2 (1 Day)
MilestoneTest Product/ Reference Product 2/ Reference Product 1Reference Product 1/ Test Product/ Reference Product 2Reference Product 2/ Reference Product 1/ Test Product
Started181718
Completed171718
Not completed100
Withdrew: Withdrawal by subject100
Washout Period 2 (3 Days)
Participant flow — Washout Period 2 (3 Days)
MilestoneTest Product/ Reference Product 2/ Reference Product 1Reference Product 1/ Test Product/ Reference Product 2Reference Product 2/ Reference Product 1/ Test Product
Started171718
Completed171718
Not completed000
Treatment Period 3 (1 Day)
Participant flow — Treatment Period 3 (1 Day)
MilestoneTest Product/ Reference Product 2/ Reference Product 1Reference Product 1/ Test Product/ Reference Product 2Reference Product 2/ Reference Product 1/ Test Product
Started171718
Completed171718
Not completed000
Washout Period 3 (3 Days)
Participant flow — Washout Period 3 (3 Days)
MilestoneTest Product/ Reference Product 2/ Reference Product 1Reference Product 1/ Test Product/ Reference Product 2Reference Product 2/ Reference Product 1/ Test Product
Started171718
Completed171718
Not completed000

Outcome measures

PrimaryMaximum Observed Concentration (Cmax) for Paracetamol ODT (Test) Versus (vs.) Paracetamol (Alvedon Film-coated Tablet) (Reference 1)

Cmax was defined as maximum observed post-dose plasma concentration for paracetamol. Blood samples were collected at indicated timepoints for the analysis of Cmax. Pharmacokinetic (PK) parameters were determined by non-compartmental analysis.

Time frame:
Within one hour prior to dosing, at 5, 10, 15, 20, 25, 30, 35, 40, 50, 60, 75, 90, 120, 150, 180 minutes and at 4, 5, 6, 8, 10, 12, 14, 16 and 24 hours following dosing in each treatment period
Reported as:
Geometric mean · micrograms per milliliter(µg/mL)
Maximum Observed Concentration (Cmax) for Paracetamol ODT (Test) Versus (vs.) Paracetamol (Alvedon Film-coated Tablet) (Reference 1)
micrograms per milliliter(µg/mL)Test ProductReference Product 1
Maximum Observed Concentration (Cmax) for Paracetamol ODT (Test) Versus (vs.) Paracetamol (Alvedon Film-coated Tablet) (Reference 1)6.27 ± 36.87.71 ± 53.6
Statistical analysis
  • Test Product vs Reference Product 1 · Ratio of geometric least square mean: 82.22 · 90% CI 76.12 to 88.8
PrimaryArea Under the Concentration vs. Time Curve From Dosing Time to the Last Measurement Time Point (AUC0-tlast) for Paracetamol ODT (Test) vs. Paracetamol (Alvedon Film-coated Tablet) (Reference 1)

AUC0-tlast was defined as area under the concentration vs. time curve from dosing time to the last measurement time point with a concentration value above the lower limit of quantitation, calculated by means of the linear up/log down method (linear trapezoidal rule for increases in concentration/logarithmic trapezoidal rule for decreases in concentrations). Blood samples were collected at indicated timepoints for the analysis of AUC0-tlast. PK parameters were determined by non-compartmental analysis.

Time frame:
Within one hour prior to dosing, at 5, 10, 15, 20, 25, 30, 35, 40, 50, 60, 75, 90, 120, 150, 180 minutes and at 4, 5, 6, 8, 10, 12, 14, 16 and 24 hours following dosing in each treatment period
Reported as:
Geometric mean · hour*microgram per milliliter (h*µg/mL)
Area Under the Concentration vs. Time Curve From Dosing Time to the Last Measurement Time Point (AUC0-tlast) for Paracetamol ODT (Test) vs. Paracetamol (Alvedon Film-coated Tablet) (Reference 1)
hour*microgram per milliliter (h*µg/mL)Test ProductReference Product 1
Area Under the Concentration vs. Time Curve From Dosing Time to the Last Measurement Time Point (AUC0-tlast) for Paracetamol ODT (Test) vs. Paracetamol (Alvedon Film-coated Tablet) (Reference 1)23.9 ± 36.624.3 ± 37.8
Statistical analysis
  • Test Product vs Reference Product 1 · Ratio of geometric least square mean: 99.23 · 90% CI 97.54 to 100.94
PrimaryTime to Reach Maximum Concentration (Tmax) for Paracetamol ODT (Test) vs. Paracetamol (Alvedon Film-coated Tablet) (Reference 1)

Blood samples were collected at indicated timepoints for the analysis of tmax. PK parameters were determined by non-compartmental analysis.

Time frame:
Within one hour prior to dosing, at 5, 10, 15, 20, 25, 30, 35, 40, 50, 60, 75, 90, 120, 150, 180 minutes and at 4, 5, 6, 8, 10, 12, 14, 16 and 24 hours following dosing in each treatment period
Reported as:
Median · hour(h)
Time to Reach Maximum Concentration (Tmax) for Paracetamol ODT (Test) vs. Paracetamol (Alvedon Film-coated Tablet) (Reference 1)
hour(h)Test ProductReference Product 1
Time to Reach Maximum Concentration (Tmax) for Paracetamol ODT (Test) vs. Paracetamol (Alvedon Film-coated Tablet) (Reference 1)1.00 (0.420 to 2.00)0.670 (0.250 to 2.52)
Statistical analysis
  • Test Product vs Reference Product 1 · Ratio of the medians: 149.25
PrimaryCmax for Paracetamol ODT (Test) vs. Paracetamol (Panadol Film-coated Tablet) (Reference 2)

Cmax was defined as maximum observed post-dose plasma concentration for paracetamol. Blood samples were collected at indicated timepoints for the analysis of Cmax. PK parameters were determined by non-compartmental analysis.

Time frame:
Within one hour prior to dosing, at 5, 10, 15, 20, 25, 30, 35, 40, 50, 60, 75, 90, 120, 150, 180 minutes and at 4, 5, 6, 8, 10, 12, 14, 16 and 24 hours following dosing in each treatment period
Reported as:
Geometric mean · µg/mL
Cmax for Paracetamol ODT (Test) vs. Paracetamol (Panadol Film-coated Tablet) (Reference 2)
µg/mLTest ProductReference Product 2
Cmax for Paracetamol ODT (Test) vs. Paracetamol (Panadol Film-coated Tablet) (Reference 2)6.27 ± 36.88.41 ± 48.6
Statistical analysis
  • Test Product vs Reference Product 2 · Ratio of geometric least square mean: 74.82 · 90% CI 68.49 to 81.73
PrimaryAUC0-tlast for Paracetamol ODT (Test) vs. Paracetamol (Panadol Film-coated Tablet) (Reference 2)

AUC0-tlast was defined as area under the concentration vs. time curve from dosing time to the last measurement time point with a concentration value above the lower limit of quantitation, calculated by means of the linear up/log down method (linear trapezoidal rule for increases in concentration/logarithmic trapezoidal rule for decreases in concentrations. Blood samples were collected at indicated timepoints for the analysis of AUC0-tlast). PK parameters were determined by non-compartmental analysis.

Time frame:
Within one hour prior to dosing, at 5, 10, 15, 20, 25, 30, 35, 40, 50, 60, 75, 90, 120, 150, 180 minutes and at 4, 5, 6, 8, 10, 12, 14, 16 and 24 hours following dosing in each treatment period
Reported as:
Geometric mean · h*µg/mL
AUC0-tlast for Paracetamol ODT (Test) vs. Paracetamol (Panadol Film-coated Tablet) (Reference 2)
h*µg/mLTest ProductReference Product 2
AUC0-tlast for Paracetamol ODT (Test) vs. Paracetamol (Panadol Film-coated Tablet) (Reference 2)23.9 ± 36.624.5 ± 34.9
Statistical analysis
  • Test Product vs Reference Product 2 · Ratio of geometric least square mean: 97.69 · 90% CI 95.75 to 99.68
PrimaryTmax for Paracetamol ODT (Test) vs. Paracetamol (Panadol Film-coated Tablet) (Reference 2)

Blood samples were collected at indicated timepoints for the analysis of tmax. PK parameters were determined by non-compartmental analysis.

Time frame:
Within one hour prior to dosing, at 5, 10, 15, 20, 25, 30, 35, 40, 50, 60, 75, 90, 120, 150, 180 minutes and at 4, 5, 6, 8, 10, 12, 14, 16 and 24 hours following dosing in each treatment period
Reported as:
Median · h
Tmax for Paracetamol ODT (Test) vs. Paracetamol (Panadol Film-coated Tablet) (Reference 2)
hTest ProductReference Product 2
Tmax for Paracetamol ODT (Test) vs. Paracetamol (Panadol Film-coated Tablet) (Reference 2)1.00 (0.420 to 2.00)0.500 (0.250 to 3.00)
Statistical analysis
  • Test Product vs Reference Product 2 · Ratio of the medians: 200
SecondaryArea Under the Plasma Concentration vs. Time Curve Calculated From Time Zero to Infinity [AUC (0-inf)] for Paracetamol ODT (Test)

AUC (0-inf) equal to(=) AUC0-tlast addition(+) AUCexpol, where AUCexpol = Clast/Lz, where Clast was observed concentration at the last time point with a concentration value above the lower limit of quantitation, directly taken from measured concentration values and Lz was apparent terminal elimination rate constant determined by log-linear regression(Lz); the regression generally involved at least 3 consecutive measurable concentrations that decreased over time. Blood samples were collected at indicated timepoints for the analysis of AUC (0-inf). PK parameters were determined by non-compartmental analysis.

Time frame:
Within one hour prior to dosing, at 5, 10, 15, 20, 25, 30, 35, 40, 50, 60, 75, 90, 120, 150, 180 minutes and at 4, 5, 6, 8, 10, 12, 14, 16 and 24 hours following dosing in each treatment period
Reported as:
Geometric mean · h*µg/mL
Area Under the Plasma Concentration vs. Time Curve Calculated From Time Zero to Infinity [AUC (0-inf)] for Paracetamol ODT (Test)
h*µg/mLTest Product
Area Under the Plasma Concentration vs. Time Curve Calculated From Time Zero to Infinity [AUC (0-inf)] for Paracetamol ODT (Test)24.6 ± 36.3
SecondaryAUC (0-inf) for Paracetamol (Alvedon Film-coated Tablet) (Reference 1)

AUC (0-inf)= AUC0-tlast + AUCexpol, where AUCexpol = Clast/Lz, where Clast was observed concentration at the last time point with a concentration value above the lower limit of quantitation, directly taken from measured concentration values and Lz was apparent terminal elimination rate constant determined by log-linear regression; the regression generally involved at least 3 consecutive measurable concentrations that decreased over time. Blood samples were collected at indicated timepoints for the analysis of AUC (0-inf). PK parameters were determined by non-compartmental analysis.

Time frame:
Within one hour prior to dosing, at 5, 10, 15, 20, 25, 30, 35, 40, 50, 60, 75, 90, 120, 150, 180 minutes and at 4, 5, 6, 8, 10, 12, 14, 16 and 24 hours following dosing in each treatment period
Reported as:
Geometric mean · h*µg/mL
AUC (0-inf) for Paracetamol (Alvedon Film-coated Tablet) (Reference 1)
h*µg/mLReference Product 1
AUC (0-inf) for Paracetamol (Alvedon Film-coated Tablet) (Reference 1)25.1 ± 37.3
SecondaryAUC (0-inf) for Paracetamol (Panadol Film-coated Tablet) (Reference 2)

AUC (0-inf)= AUC0-tlast + AUCexpol, where AUCexpol = Clast/Lz, where Clast was observed concentration at the last time point with a concentration value above the lower limit of quantitation, directly taken from measured concentration values and Lz was apparent terminal elimination rate constant determined by log-linear regression; the regression generally involved at least 3 consecutive measurable concentrations that decreased over time. Blood samples were collected at indicated timepoints for the analysis of AUC (0-inf). PK parameters were determined by non-compartmental analysis.

Time frame:
Within one hour prior to dosing, at 5, 10, 15, 20, 25, 30, 35, 40, 50, 60, 75, 90, 120, 150, 180 minutes and at 4, 5, 6, 8, 10, 12, 14, 16 and 24 hours following dosing in each treatment period
Reported as:
Geometric mean · h*µg/mL
AUC (0-inf) for Paracetamol (Panadol Film-coated Tablet) (Reference 2)
h*µg/mLReference Product 2
AUC (0-inf) for Paracetamol (Panadol Film-coated Tablet) (Reference 2)25.3 ± 34.6
SecondaryAUCexpol% for Paracetamol ODT (Test)

AUCexpol%= AUCexpol multiplied by (\*)100/AUC0-inf, where AUCexpol = Clast/Lz. Blood samples were collected at indicated timepoints for the analysis of AUCexpol%. PK parameters were determined by non-compartmental analysis.

Time frame:
Within one hour prior to dosing, at 5, 10, 15, 20, 25, 30, 35, 40, 50, 60, 75, 90, 120, 150, 180 minutes and at 4, 5, 6, 8, 10, 12, 14, 16 and 24 hours following dosing in each treatment period
Reported as:
Geometric mean · percentage
AUCexpol% for Paracetamol ODT (Test)
percentageTest Product
AUCexpol% for Paracetamol ODT (Test)2.57 ± 43.1
SecondaryAUCexpol% for Paracetamol (Alvedon Film-coated Tablet) (Reference 1)

AUCexpol%= AUCexpol\*100/AUC0-inf, where AUCexpol = Clast/Lz. Blood samples were collected at indicated timepoints for the analysis of AUCexpol%. PK parameters were determined by non-compartmental analysis.

Time frame:
Within one hour prior to dosing, at 5, 10, 15, 20, 25, 30, 35, 40, 50, 60, 75, 90, 120, 150, 180 minutes and at 4, 5, 6, 8, 10, 12, 14, 16 and 24 hours following dosing in each treatment period
Reported as:
Geometric mean · percentage
AUCexpol% for Paracetamol (Alvedon Film-coated Tablet) (Reference 1)
percentageReference Product 1
AUCexpol% for Paracetamol (Alvedon Film-coated Tablet) (Reference 1)2.74 ± 44.8
SecondaryAUCexpol% for Paracetamol (Panadol Film-coated Tablet) (Reference 2)

AUCexpol%= AUCexpol\*100/AUC0-inf, where AUCexpol = Clast/Lz. Blood samples were collected at indicated timepoints for the analysis of AUCexpol%. PK parameters were determined by non-compartmental analysis.

Time frame:
Within one hour prior to dosing, at 5, 10, 15, 20, 25, 30, 35, 40, 50, 60, 75, 90, 120, 150, 180 minutes and at 4, 5, 6, 8, 10, 12, 14, 16 and 24 hours following dosing in each treatment period
Reported as:
Geometric mean · percentage
AUCexpol% for Paracetamol (Panadol Film-coated Tablet) (Reference 2)
percentageReference Product 2
AUCexpol% for Paracetamol (Panadol Film-coated Tablet) (Reference 2)2.64 ± 56.5
SecondaryLz for Paracetamol ODT (Test)

Lz was an apparent terminal elimination rate constant determined by log-linear regression; the regression generally involved at least 3 consecutive measurable concentrations that decreased over time. Blood samples were collected at indicated timepoints for the analysis of Lz. PK parameters were determined by non-compartmental analysis.

Time frame:
Within one hour prior to dosing, at 5, 10, 15, 20, 25, 30, 35, 40, 50, 60, 75, 90, 120, 150, 180 minutes and at 4, 5, 6, 8, 10, 12, 14, 16 and 24 hours following dosing in each treatment period
Reported as:
Geometric mean · 1/h
Lz for Paracetamol ODT (Test)
1/hTest Product
Lz for Paracetamol ODT (Test)0.148 ± 30.3
SecondaryLz for Paracetamol (Alvedon Film-coated Tablet) (Reference 1)

Lz was an apparent terminal elimination rate constant determined by log-linear regression; the regression generally involved at least 3 consecutive measurable concentrations that decreased over time. Blood samples were collected at indicated timepoints for the analysis of Lz. PK parameters were determined by non-compartmental analysis.

Time frame:
Within one hour prior to dosing, at 5, 10, 15, 20, 25, 30, 35, 40, 50, 60, 75, 90, 120, 150, 180 minutes and at 4, 5, 6, 8, 10, 12, 14, 16 and 24 hours following dosing in each treatment period
Reported as:
Geometric mean · 1/h
Lz for Paracetamol (Alvedon Film-coated Tablet) (Reference 1)
1/hReference Product 1
Lz for Paracetamol (Alvedon Film-coated Tablet) (Reference 1)0.140 ± 30.1
SecondaryLz for Paracetamol (Panadol Film-coated Tablet) (Reference 2)

Lz was an apparent terminal elimination rate constant determined by log-linear regression; the regression generally involved at least 3 consecutive measurable concentrations that decreased over time. Blood samples were collected at indicated timepoints for the analysis of Lz. PK parameters were determined by non-compartmental analysis.

Time frame:
Within one hour prior to dosing, at 5, 10, 15, 20, 25, 30, 35, 40, 50, 60, 75, 90, 120, 150, 180 minutes and at 4, 5, 6, 8, 10, 12, 14, 16 and 24 hours following dosing in each treatment period
Reported as:
Geometric mean · 1/h
Lz for Paracetamol (Panadol Film-coated Tablet) (Reference 2)
1/hReference Product 2
Lz for Paracetamol (Panadol Film-coated Tablet) (Reference 2)0.143 ± 34.8
SecondaryApparent Terminal Elimination Half-life (t1/2) for Paracetamol ODT (Test)

t1/2 = ln(2) / Lz. Blood samples were collected at indicated timepoints for the analysis of t1/2. PK parameters were determined by non-compartmental analysis.

Time frame:
Within one hour prior to dosing, at 5, 10, 15, 20, 25, 30, 35, 40, 50, 60, 75, 90, 120, 150, 180 minutes and at 4, 5, 6, 8, 10, 12, 14, 16 and 24 hours following dosing in each treatment period
Reported as:
Median · h
Apparent Terminal Elimination Half-life (t1/2) for Paracetamol ODT (Test)
hTest Product
Apparent Terminal Elimination Half-life (t1/2) for Paracetamol ODT (Test)4.73 (2.67 to 10.7)
Secondaryt1/2 for Paracetamol (Alvedon Film-coated Tablet) (Reference 1)

t1/2 = ln(2) / Lz. Blood samples were collected at indicated timepoints for the analysis of t1/2. PK parameters were determined by non-compartmental analysis.

Time frame:
Within one hour prior to dosing, at 5, 10, 15, 20, 25, 30, 35, 40, 50, 60, 75, 90, 120, 150, 180 minutes and at 4, 5, 6, 8, 10, 12, 14, 16 and 24 hours following dosing in each treatment period
Reported as:
Median · h
t1/2 for Paracetamol (Alvedon Film-coated Tablet) (Reference 1)
hReference Product 1
t1/2 for Paracetamol (Alvedon Film-coated Tablet) (Reference 1)5.03 (2.67 to 8.96)
Secondaryt1/2 for Paracetamol (Panadol Film-coated Tablet) (Reference 2)

t1/2 = ln(2) / Lz. Blood samples were collected at indicated timepoints for the analysis of t1/2. PK parameters were determined by non-compartmental analysis.

Time frame:
Within one hour prior to dosing, at 5, 10, 15, 20, 25, 30, 35, 40, 50, 60, 75, 90, 120, 150, 180 minutes and at 4, 5, 6, 8, 10, 12, 14, 16 and 24 hours following dosing in each treatment period
Reported as:
Median · h
t1/2 for Paracetamol (Panadol Film-coated Tablet) (Reference 2)
hReference Product 2
t1/2 for Paracetamol (Panadol Film-coated Tablet) (Reference 2)4.75 (2.53 to 12.5)

Adverse events

Collected over Immediately after a participant provided consent to participate in the study up to day 2 of period 3 (Approximately up to 32 days).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Test Product0/53 (0%)0/53 (0%)12/53 (22.6%)
Reference Product 10/53 (0%)0/53 (0%)16/53 (30.2%)
Reference Product 20/53 (0%)0/53 (0%)9/53 (17%)
Most frequent other events
Showing 10 of 24
Most frequent other events
EventTest ProductReference Product 1Reference Product 2
PresyncopeNervous system disorders1/533/531/53
HeadacheNervous system disorders0/533/531/53
NauseaGastrointestinal disorders2/531/530/53
Abdominal distensionGastrointestinal disorders1/530/530/53
Abdominal pain upperGastrointestinal disorders1/530/530/53
Urinary tract infectionInfections and infestations1/530/531/53
Blood cholesterol increasedInvestigations1/530/530/53
Blood pressure diastolic increasedInvestigations1/531/531/53
Blood pressure increasedInvestigations1/530/530/53
Blood thyroid stimulating hormone increasedInvestigations1/530/531/53

Baseline characteristics

The Safety Population included all randomised participants who received at least one dose of study medication.

Age, Continuous
Age, Continuous(years)Overall Study Participants
Mean37 ± 9.8
Sex: Female, Male
Sex: Female, Male(Participants)Overall Study Participants
Female27
Male27
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Overall Study Participants
08

Study locations

1 site
  • SocraTec R&D GmbH
    Erfurt, Thuringia 99084, Germany
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual participant data and study documents can be requested for further research from ww.clinical-trialregister@haleon.com.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension can be granted, when justified, for up to another 12 months.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2025 to primary completion in Apr 2025, 1 month.

Results were first posted in Jul 2026, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 28, 2025
First posted
Mar 4, 2025
StartActual
Mar 5, 2025
Primary completionActual
Apr 17, 2025
CompletionActual
Apr 17, 2025
Results first posted
Jul 1, 2026
Last update
Jul 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06855576
Lead sponsor
HALEON
Responsible party
Sponsor
First posted
Mar 4, 2025
Start date
Mar 5, 2025
Primary completion
Apr 17, 2025
Completion
Apr 17, 2025
Results posted
Jul 1, 2026
Last update
Jul 1, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Acetaminophen

Start the discussion